Talwalkar Y B, Harner M H, Musgrave J E, Lawson R K, Campbell R A
West J Med. 1975 Jul;123(1):1-6.
Thirty-one children received 38 kidney transplants from 22 live and 16 cadaver donors. Among the 31 patients, 25 received one transplant each, 5 received two transplants each and 1 received three transplants. Peritoneal or hemodialysis (or both) was carried out in 22 patients, with an average dialytic maintenance of 12 weeks before transplantation. Posttransplant immunosuppressive therapy included prednisone and azathioprine. Antilymphocyte globulin was administered to 33 recipients as adjunctive immunosuppressive therapy. At present, 23 patients have functioning allografts, 3 are on hemodialysis and 5 are dead. Of 22 live kidney transplants, 18 are presently functioning two months to 14 years after transplantation with an average of 36 months. Of 16 cadaver kidney transplants, 5 are presently functioning 9 to 57 months after transplantation with an average of 32 months. Actuarial live donor allograft survival for one year was 76 percent, for two years was 66 percent and for three years was 64 percent. Cadaver allograft survival was 50 percent, 40 percent and 40 percent, respectively. Complications were urologic and infection related. Of nine recipients with sustained hypertension, in six the condition was due to chronic rejection, while in one it was due to recurrence of the original disease in the allograft. Linear growth was measured in 15 children who were less than 14 years of age at the time of transplantation and in whom allografts survived more than one year. Maximum average linear growth velocity occurred during the first year after transplantation. Our experience indicates pediatric renal transplantation can be successfully used in the treatment of terminal renal failure.
31名儿童接受了来自22名活体供者和16名尸体供者的38次肾移植。在这31名患者中,25人接受了一次移植,5人接受了两次移植,1人接受了三次移植。22名患者接受了腹膜透析或血液透析(或两者皆有),移植前平均透析维持时间为12周。移植后免疫抑制治疗包括泼尼松和硫唑嘌呤。33名受者接受了抗淋巴细胞球蛋白作为辅助免疫抑制治疗。目前,23名患者的同种异体移植肾功能良好,3人接受血液透析,5人死亡。在22次活体肾移植中,18次目前在移植后2个月至14年仍有功能,平均时间为36个月。在16次尸体肾移植中,5次目前在移植后9至57个月仍有功能,平均时间为32个月。活体供者同种异体移植的1年、2年和3年精算生存率分别为76%、66%和64%。尸体同种异体移植的生存率分别为50%、40%和40%。并发症与泌尿系统和感染有关。在9名持续性高血压受者中,6人的病情是由于慢性排斥反应,而1人的病情是由于同种异体移植中原有疾病的复发。对15名移植时年龄小于14岁且同种异体移植存活超过1年的儿童进行了线性生长测量。最大平均线性生长速度出现在移植后的第一年。我们的经验表明,小儿肾移植可成功用于终末期肾衰竭的治疗。